According to Ultragenyx Pharmaceutical's latest financial reports the company has NZ$0.25 Billion in net assets.
A companyโs net assets is the sum of its assets minus the sum of its liabilities.
Year | Net assets | Change |
---|---|---|
2024-12-31 | $NZ$0.46 B | 6.79% |
2023-12-31 | $NZ$0.43 B | -21.56% |
2022-12-31 | $NZ$0.55 B | -58.89% |
2021-12-31 | $NZ$1.35 B | -15.58% |
2020-12-31 | $NZ$1.59 B | 64.81% |
2019-12-31 | $NZ$0.97 B | 6.94% |
2018-12-31 | $NZ$0.90 B | 68.13% |
2017-12-31 | $NZ$0.53 B | -21.09% |
2016-12-31 | $NZ$0.68 B | -11.82% |
2015-12-31 | $NZ$0.77 B | 228.74% |
2014-12-31 | $NZ$0.23 B | 287.1% |
2013-12-31 | $NZ$60.97 M | -40.52% |
2012-12-31 | $NZ$0.10 B | 651.81% |
2011-12-31 | $NZ$13.63 M |
Company | Net assets | differencediff. | Country |
---|---|---|---|
![]() BioMarin Pharmaceutical BMRN | NZ$9.72 B | 3,730.49% | ๐บ๐ธ USA |
![]() Amicus Therapeutics
FOLD | NZ$0.32 B | 27.98% | ๐บ๐ธ USA |
![]() Esperion Therapeutics ESPR | -NZ$0.72 Billion | -381.80% | ๐บ๐ธ USA |
![]() Lexicon Pharmaceuticals
LXRX | NZ$0.20 B | -18.65% | ๐บ๐ธ USA |